PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia on November 11-13, 2023.

加利福尼亚州帕萨迪纳-（商业线）-Arrowhead Pharmaceuticals Inc.（纳斯达克股票代码：ARWR）今天宣布，它将提供来自正在进行的SHASTA-2和MUIR plozasiran研究（ARO-APOC3）的新的2期临床数据，以及于2023年11月11日至13日在费城举行的美国心脏协会（AHA）科学会议2023年zodasiran（ARO-ANG3）的ARCHES-2研究。

The company will also host a virtual analyst and investor event on November 13, 2023, at 4:30 pm ET featuring key opinion leaders who will discuss these data and their relevance as potential treatments for severe hypertriglyceridemia and mixed dyslipidemia in patients with atherosclerotic cardiovascular disease (ASCVD).

该公司还将于2023年11月13日下午4:30举办虚拟分析师和投资者活动，主要意见领袖将讨论这些数据及其作为动脉粥样硬化心血管患者严重高甘油三酯血症和混合性血脂异常的潜在治疗方法的相关性。疾病（ASCVD）。

To register for the event, please visit: https://lifescievents.com/event/arrowhead/..

要注册该活动，请访问：https://lifescievents.com/event/arrowhead/..

Details about the AHA presentations are listed below.

下面列出了有关AHA演示文稿的详细信息。

American Heart Association (AHA) Scientific Sessions 2023 – November 11-13, 2023

美国心脏协会（AHA）科学会议2023-2023年11月11日至13日

Title: ARO-APOC3, an Investigational RNAi Therapeutic, Silences APOC3 and Reduces Triglycerides to Near Normal Levels in Patients With Severe Hypertriglyceridemia: SHASTA-2 Study Results

题目：ARO-APOC3，一种研究性RNAi治疗药物，可使严重高甘油三酯血症患者的APOC3沉默并使甘油三酯降低至接近正常水平：SHASTA-2研究结果

Date/Time: November 13, 2023, 9:45 a.m. EST

日期/时间：2023年11月13日，美国东部时间上午9:45

Presenter: Daniel Gaudet

主持人：Daniel Gaudet

Session: Lipid Lowering via Novel Pathways

会议：通过新途径降低血脂

Title: ARO-APOC3, an Investigational RNAi Therapeutic, Silences APOC3 and Reduces Atherosclerosis-Associated Lipoproteins in Patients With Mixed Dyslipidemia: MUIR Study Results

题目：ARO-APOC3，一种研究性RNAi治疗药物，可沉默APOC3并减少混合性血脂异常患者的动脉粥样硬化相关脂蛋白：MUIR研究结果

Date/Time: November 13, 2023, 1:30 p.m. EST

日期/时间：2023年11月13日，美国东部时间下午1:30

Presenter: Christie M Ballantyne

主持人：Christie M Ballantyne

Session: Emerging Approaches to Lipid Lowering

会议：新兴的降脂方法

Title: ARO-ANG3, an Investigational RNAi Therapeutic, Silences the Expression of ANGPTL3 and Decreases Atherogenic Lipoproteins in Patients With Mixed Dyslipidemia: ARCHES-2 Study Results

题目：ARO-ANG3是一种研究性RNAi治疗药物，可抑制混合性血脂异常患者ANGPTL3的表达并降低致动脉粥样硬化脂蛋白：ARCHES-2研究结果

Date/Time: November 13, 2023, 1:30 p.m. EST

日期/时间：2023年11月13日，美国东部时间下午1:30

Presenter: Robert S Rosenson

主持人：Robert S Rosenson

Session: Emerging Approaches to Lipid Lowering

会议：新兴的降脂方法

The analyst and investor event will feature presentations from Arrowhead management and three experts in the treatment and management of lipid and lipoprotein disorders:

分析师和投资者活动将以箭头管理层和三位脂质和脂蛋白疾病治疗和管理专家的演讲为特色：

Daniel Gaudet, MD, PhD, Professor of Medicine at Université de Montréal, who will discuss plozasiran in the context of the current treatment landscape for severe hypertriglyceridemia

蒙特利尔大学医学教授Daniel Gaudet博士将在目前严重高甘油三酯血症治疗领域讨论普罗扎西兰

Børge Nordestgaard, MD, Professor & Chief Physician, Copenhagen University Hospital, University of Copenhagen, Denmark, who will discuss remnant cholesterol and its role in cardiovascular disease

丹麦哥本哈根大学哥本哈根大学医院教授兼主任医师B rge Nordestgaard将讨论残余胆固醇及其在心血管疾病中的作用

Steven Nissen, MD, Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic, who will discuss the potential of a cardiovascular outcomes study of plozasiran

克利夫兰诊所心脏和血管研究所首席学术官Steven Nissen博士将讨论plozasiran心血管预后研究的潜力

Expert Bios

专家生物

Daniel Gaudet, MD, PhD, is Professor of Medicine at Université de Montréal (UdeM) and leads the UdeM Community Genetic Medicine Center and its Clinical Lipidology and Rare Lipid Disorders Unit. He is currently president and scientific director of ECOGENE-21, a non-for profit organization devoted to access to innovation in precision medicine.

Daniel Gaudet博士是蒙特利尔大学（UdeM）的医学教授，并领导UdeM社区遗传医学中心及其临床脂质学和罕见脂质疾病部门。他现任ECOGENE-21的总裁兼科学总监，ECOGENE-21是一家致力于精准医学创新的非营利组织。

His main clinical and academic activities aim at investigating rare or severe dyslipidemias and translating new knowledge issued from extreme phenotypes to more common forms of diseases. Over the years, he has coordinated more than 200 clinical studies involving the development of screening tools, technologies or emerging therapies for severe dyslipidemias or related disorders, in collaboration with biotechs, pharmas, or academic partners.

他的主要临床和学术活动旨在调查罕见或严重的血脂异常，并将从极端表型发出的新知识转化为更常见的疾病形式。多年来，他与生物技术，制药公司或学术合作伙伴合作，协调了200多项临床研究，涉及开发针对严重血脂异常或相关疾病的筛查工具，技术或新兴疗法。

He authored more than 320 scientific publications in peer-reviewed journals, including several tens in very highly rated Journals (NEJM, Nature Medicine, Eur Heart J, Lancet, Nature Genetics) as well as >500 scientific communications or book chapters..

他在同行评议的期刊上发表了320多篇科学出版物，其中包括几十篇被高度评价的期刊（NEJM，Nature Medicine，Eur Heart J，Lancet，Nature Genetics）以及500多篇科学交流或书籍章节。。

Børge G. Nordestgaard, MD, DMSc, is Professor & Chief Physician, Copenhagen University Hospital, University of Copenhagen, Denmark, and President-Elect European Atherosclerosis Society. Prof Nordestgaard studied and worked in Copenhagen, New York, and London. He has for more than 30 years continued his interest in the pathogenesis, diagnosis and treatment of familial hypercholesterolemia, hyperlipidemia, lipoprotein(a), atherosclerosis, diabetes and cardiovascular disease, and has written extensively on these conditions.

BørgeG。Nordestgaard，医学博士，DMSc，丹麦哥本哈根大学哥本哈根大学医院教授兼首席医师，欧洲动脉粥样硬化学会主席。Nordestgaard教授在哥本哈根，纽约和伦敦学习和工作。30多年来，他一直对家族性高胆固醇血症，高脂血症，脂蛋白（a），动脉粥样硬化，糖尿病和心血管疾病的发病机理，诊断和治疗感兴趣，并对这些疾病进行了广泛的研究。

He is chairing the Copenhagen General Population Study and is a steering committee member of the Copenhagen City Heart Study and five phase 3 cardiovascular intervention trials. Prof. Nordestgaard has supervised 74 Ph.D. students and 34 postdoctoral fellows, and has published 920 original articles and 140 reviews, book chapters, consensus statements, & editorials.

他是哥本哈根一般人口研究的主席，是哥本哈根市心脏研究和五个三期心血管干预试验的指导委员会成员。Nordestgaard教授监督了74名博士生和34名博士后，发表了920篇原创文章和140篇评论，书籍章节，共识声明和社论。

His H-index is 152 in Web of Science and he is listed among the top 0.1% researchers worldwide with the most highly cited papers. Original articles include publications in New England Journal of Medicine, Lancet, Journal of the American Medical Association, Nature, Science, Nature Genetics, British Medical Journal, Lancet Diabetes Endocrinology, Circulation, European Heart Journal, Journal of the American College of Cardiology and JAMA cardiology..

他的H指数在Web of Science中为152，在全球排名前0.1%的研究人员中排名最高，被引用次数最多。原始文章包括新英格兰医学杂志，柳叶刀，美国医学会杂志，自然，科学，自然遗传学，英国医学杂志，柳叶刀糖尿病内分泌学，循环，欧洲心脏杂志，美国心脏病学会杂志和JAMA心脏病学。。

Steven E. Nissen MD is Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic, the Lewis and Patricia Dickey Chair in Cardiovascular Medicine and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. From 2006 to 2019, he served as Chair of the Department of Cardiovascular Medicine at the Cleveland Clinic.

Steven E.Nissen医学博士是克利夫兰诊所心脏和血管研究所的首席学术官，Lewis和Patricia Dickey心血管医学主席以及凯斯西储大学克利夫兰诊所勒纳医学院的医学教授。从2006年到2019年，他担任克利夫兰诊所心血管内科主任。

In 2006-2007 he served as President of the American College of Cardiology (ACC), the professional society representing American cardiologists..

2006-2007年，他担任美国心脏病学会（ACC）主席，该学会代表美国心脏病学家。。

His initial research focused on application of intravascular ultrasound (IVUS) imaging to the assessment of progression and regression of coronary atherosclerosis, conducting more than a dozen randomized controlled trials, most published in the NEJM or JAMA. More recently, he has served as Study Chairman for large global cardiovascular outcomes trials, most studying lipid modifying therapies.

他最初的研究集中在应用血管内超声（IVUS）成像评估冠状动脉粥样硬化的进展和消退，进行了十几项随机对照试验，大多数发表在NEJM或JAMA上。最近，他曾担任大型全球心血管预后试验的研究主席，大多数研究脂质修饰疗法。

His contributions to scientific literature include more than 600 journal articles and 60 book chapters. He is co-author of a book for patients with heart disease, Heart411 released by Crown Books on January 31, 2012..

他对科学文献的贡献包括600多篇期刊文章和60章书籍。他是2012年1月31日Crown Books出版的心脏病患者书Heart411的合着者。。

Dr. Nissen works closely with pharmaceutical companies on the development of new therapies for cardiovascular disease, but maintains a longstanding policy of requiring companies to donate all related honoraria directly to charity so that he receives neither income, nor a tax deduction.

Nissen博士与制药公司密切合作开发心血管疾病新疗法，但一直坚持要求公司直接向慈善机构捐赠所有相关酬金的长期政策，以便他既不收入也不扣除税收。

He has also written extensively on the subject of drug safety. In 2001, he co-authored the first manuscript (JAMA) that raised concerns about the cardiovascular safety of rofecoxib (Vioxx™), which was withdrawn from the market 3 years later. In 2007, he authored a NEJM manuscript that demonstrated that the widely used diabetes drug rosiglitazone (Avandia™) raised the risk of myocardial infarction, eventually leading in 2010 to withdrawal of the drug in Europe and severe restrictions in the US..

他还在药物安全问题上写了广泛的文章。2001年，他共同撰写了第一份手稿（JAMA），该手稿引起了人们对罗非昔布（Vioxx™), 3年后退出市场。2007年，他撰写了NEJM手稿，证明了广泛使用的糖尿病药物罗格列酮（Avandia™) 增加了心肌梗塞的风险，最终导致2010年在欧洲停药并在美国严格限制。。

Dr. Nissen served as a member of the CardioRenal Advisory Panel of Food and Drug Administration (FDA) for 5 years, and Chairman the final year of his membership. He continues to serve as Advisor to several FDA committees as a “Special Government Employee”. In July 2008, while serving as guest member of the Endocrine and Metabolism Advisory Panel, he recommended a new approach for approval of diabetes drugs, which was ultimately adopted by the Agency in December 2008..

Nissen博士担任食品和药物管理局（FDA）心肾咨询小组成员5年，并担任其成员最后一年主席。作为“特殊政府雇员”，他继续担任多个FDA委员会的顾问。2008年7月，在担任内分泌和代谢咨询小组客座成员的同时，他推荐了一种新的批准糖尿病药物的方法，该方法最终于2008年12月被该机构采用。。

Dr. Nissen is also known for his role in public policy discussions. He has testified in both the Senate (Health Education and Labor Committee) and House of Representatives (Energy and Commerce Committee) on Food and Drug Administration (FDA) policy. He was actively involved in discussions with Congress on the FDA Amendments Act of 2007 that added additional regulatory authority for the Agency..

Nissen博士也因其在公共政策讨论中的作用而闻名。他在参议院（健康教育和劳动委员会）和参议院（能源和商业委员会）就食品和药物管理局（FDA）的政策辩护。他积极参与了与国会就2007年FDA修正法案的讨论，该法案为该机构增加了额外的监管机构。。

In 2007, Time Magazine selected Dr. Nissen as one of the world’s 100 most influential people. Beginning in 2015, he was named by Thompson-Reuters as one of the world’s most highly cited physician-scientists.

“华尔街日报”2007年将尼森博士选为世界上100位最有影响力的人物之一。从2015年开始，他被汤普森路透（Thompson Reuters）命名为世界上被引用次数最多的医学科学家之一。

A copy of the presentation materials and a webcast link for the analyst and investor event will be available on the Events and Presentations page under the Investors section of the Arrowhead website.

分析师和投资者活动的演示材料和网络广播链接的副本将在箭头网站投资者部分的活动和演示页面上提供。

About Arrowhead Pharmaceuticals

关于箭头制药

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

箭头药物通过沉默导致它们的基因来开发治疗难治性疾病的药物。箭头疗法利用广泛的RNA化学和有效的递送模式，触发RNA干扰机制，诱导靶基因的快速，深度和持久的敲低。

RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing..

RNA干扰或RNAi是存在于活细胞中的机制，其抑制特定基因的表达，从而影响特定蛋白质的产生。Arrowhead基于RNAi的疗法利用这种基因沉默的自然途径。。

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

欲了解更多信息，请访问www.arrowheadpharma.com，或在Twitter@arrowheadpharma上关注我们。要添加到公司的电子邮件列表中并直接接收新闻，请访问http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

“私人证券诉讼改革法”下的安全港声明：

This news release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements.

本新闻稿包含1995年“私人证券诉讼改革法”“安全港”规定含义的前瞻性陈述。除历史信息外，本版本中包含的任何声明均视为前瞻性声明。在不限制上述内容的一般性的情况下，诸如“可以”，“将会”，“期望”，“相信”，“期望”，“希望”，“意图”，“计划”，“项目”，“可以”，“估计”，“继续”，“目标”，“预测”或“继续”之类的词语或其其他变体或可比较的术语旨在识别此类前瞻性陈述。

In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements.

此外，任何涉及我们未来财务绩效预测，业务趋势，对我们产品线或产品候选人的期望的声明，包括预期的监管提交和临床计划结果，我们与其他公司合作的前景或收益，或对未来事件或情况的其他描述是前瞻性陈述。

These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.

这些前瞻性陈述包括但不限于关于我们的临床前研究和临床试验以及我们的研究和开发计划的启动，时间，进展和结果的陈述；我们对合伙关系，许可和/或合作安排以及我们已签订或可能签订的其他战略安排和交易的潜在利益的期望；我们对现有协议下可能由第三方或第三方支付的里程碑，版税或其他付款的信念和期望；以及我们对未来收入，研发费用，资本要求和向第三方支付的估计。

These statements are based u.

这些陈述是以u为基础的。

Source: Arrowhead Pharmaceuticals, Inc.

来源：Arrowhead Pharmaceuticals，Inc。